S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

OSTX OS Therapies Incorporated

1.68

-0.02 (-1.18%)

Feb 24 2025 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more OS Therapies Charts.

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more OS Therapies Charts.

OS Therapies Incorporated News

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Monday 24 February 2025 (17 hours ago) • Business Wire

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Thursday 20 February 2025 (5 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 18 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 5 - Annual statement of changes in beneficial ownership of securities
Friday 14 February 2025 (1 week ago) • Edgar (US Regulatory)

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Friday 14 February 2025 (2 weeks ago) • Business Wire

Form PRE 14A - Other preliminary proxy statements
Friday 7 February 2025 (2 weeks ago) • Edgar (US Regulatory)

OS Therapies Provides Corporate Update
Tuesday 4 February 2025 (3 weeks ago) • Business Wire

Form S-1 - General form for registration of securities under the Securities Act of 1933
Friday 31 January 2025 (3 weeks ago) • Edgar (US Regulatory)

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
Wednesday 29 January 2025 (4 weeks ago) • Business Wire

Form 8-K - Current report
Wednesday 29 January 2025 (4 weeks ago) • Edgar (US Regulatory)

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
Wednesday 29 January 2025 (4 weeks ago) • Business Wire

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
Friday 17 January 2025 (1 month ago) • Edgar (US Regulatory)

More OS Therapies Incorporated News Articles

TPT Global Tech (PK)

Accredited Solutions (PK)

Intergrated Cannabis Sol... (PK)

Valiant Eagle (PK)

Lightwave Logic

Asia Broadband (PK)

NioCorp Developments

Kraig Biocraft Laborator... (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions